Exagen sets dates for second-quarter results, shares watched around Nasdaq listing

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-25, 22:21.

Exagen Inc (US30063K1051) has set the timetable for its second-quarter 2026 earnings release and conference call. The Nasdaq-listed diagnostics company detailed the late-July schedule in a fresh investor update, giving shareholders a clearer view of the coming reporting date and communications plan. Exagen investor relations calendar

What the latest Exagen update says

Per Exagen Inc's investor relations page, management plans to publish second-quarter 2026 financial results and host an earnings call toward the end of July, with exact day and dial-in details already posted for investors. The company, which trades on Nasdaq in New York alongside peers such as Exact Sciences, uses the call to review revenue trends and cash metrics with analysts and shareholders. Nasdaq listing data for Exagen

The newly confirmed timetable ties in with broader U.S. earnings season, when multiple healthcare and diagnostics names report quarterly numbers and update guidance. For Exagen, the published schedule underscores the company’s intention to maintain regular communication on operational progress, test volumes and market access in rheumatology and autoimmune disease diagnostics.

Upcoming earnings in a busy July calendar

Across the U.S. market, July 2026 is shaping up as a dense reporting window, with several financial and healthcare companies already having announced late-month calls, as recent company announcements compiled by the Financial Times show. Exagen’s late-July slot places it after a number of larger financial institutions but within the same general time frame as other mid-cap medical and diagnostics firms, giving investors a concentrated period to compare results and strategies. Financial Times company announcements overview

For retail investors following diagnostics and life science tools, the fixed Exagen date offers a concrete point to reassess expectations on revenue growth, cash burn and potential updates on commercial partnerships. Earnings calls in this segment often include commentary on reimbursement, payor coverage and test adoption, topics that can materially influence small-cap trading sentiment.

The diagnostics focus in Exagen’s business

Exagen’s core business centers on specialty laboratory tests designed to support the diagnosis and management of autoimmune and rheumatologic diseases, with its AVISE family of tests as a key commercial line. The AVISE CTD panel, for example, integrates multiple biomarkers to assist physicians in assessing connective tissue diseases such as lupus, aiming to improve clinical decision-making and reduce diagnostic uncertainty.

Where the stock trades today

Exagen Inc shares trade on Nasdaq in the United States under the ticker XGN, with the latest quote in U.S. dollars reflecting the company’s small-cap status in the healthcare diagnostics segment as of 2026-06-25.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.